Tyrosine News and Research

RSS

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.

1 Nov 2016

Benefit and harm of tandem mass spectrometry screening for tyrosinaemia type 1 remain unclear

Tyrosinaemia type 1 is a rare, hereditary metabolic disease that, if left untreated, can already lead to serious liver and kidney damage in infancy.

25 Oct 2016

Yale researchers identify chemical inhibitor that limits growth of lung tumor cells

A recently published Yale study may offer a new solution to fighting lung cancer.

20 Oct 2016

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.

30 Sep 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.

28 Sep 2016

Association for Molecular Pathology announces winners of 2016 awards

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostics professionals, today announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting.

27 Sep 2016

Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy.

19 Sep 2016

Study identifies new gene that suppresses breast cancer in mice

In recent years, the incidence of breast cancer has been increasing worldwide, and breast cancer is becoming a serious object of public concern.

13 Sep 2016

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too.

6 Sep 2016

Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.

16 Aug 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment.

12 Jul 2016

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies.

12 Jul 2016

Researchers discover new signaling events that trigger metastasis in ovarian cancer cells

Like pancreatic cancer, cancer of the ovaries is notorious for being discovered at a relatively late stage - after it has spread to other sites in the body. It is not called "the silent killer" for nothing.

11 Jul 2016

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group and the University Hospitals Leuven, has discovered various potential biomarkers predictive of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer.

8 Jul 2016

Nutritional interventions may help prevent detrimental brain ageing

Ageing is a highly complex process marked by a succession of events that may lead to an altered brain function, including neurodegenerative diseases. To date, the precise cause of cognitive decline remains quite elusive.

1 Jul 2016

ALK fusion variants could influence NSCLC crizotinib response

In non-small-cell lung cancer patients with anaplastic lymphoma kinase rearrangement treated with crizotinib, progression-free survival varies according to the ALK fusion variant.